• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
August 27, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
August 12, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
July 25, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
July 24, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
July 11, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
July 09, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
July 01, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Declares Third-Quarter 2024 Dividend
June 26, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
June 18, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
June 14, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
June 12, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 03, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
June 01, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
May 31, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces New Chief Strategy and Innovation Officer
May 06, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Reports First-Quarter 2024 Results
May 01, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
News headline image
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
April 29, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
April 26, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Declares Second-Quarter 2024 Dividend
April 24, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
April 22, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
April 11, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
April 09, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
March 20, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
March 13, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
March 12, 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap